AN OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DIDEOXYCYTIDINE (DDC) IN PATIENTS WITH AIDS OR ADVANCED ARC WHO PREVIOUSLY DEMONSTRATED INTOLERANCE TO ZIDOVUDINE (AZT) IN PROTOCOL N3300 OR N3492: